November 30, 2017 / 6:36 PM / 17 days ago

BRIEF-Asit Biotech Publishes Phase IIb Clinical Results With gp-ASIT+

Nov 30 (Reuters) - ASIT BIOTECH SA:

* ASIT BIOTECH: NEWLY PUBLISHED PHASE IIB CLINICAL RESULTS WITH GP-ASIT+ IN THE ALLERGY JOURNAL HIGHLIGHT OUTSTANDING CLINICAL AND REMARKABLE IMMUNOLOGICAL EFFECTS

* ‍STUDY RESULTS ALSO CONFIRMED THAT GP-ASIT+ IS SAFE AND WELL TOLERATED​

* ‍CLINICAL AND IMMUNOLOGICAL EFFECTS OBSERVED IN THIS PHASE IIB HAVE BEEN CONFIRMED IN FIRST PHASE III​

* ‍RESULTS OF THIS PHASE III TRIAL WILL BE PUBLISHED SOON IN A PEER-REVIEWED JOURNAL​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below